Literature DB >> 32585057

Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma.

Chao Gu1, Katherine Upchurch2, James Mamaril-Davis1, Matthew Wiest1,2, Bobby Lanier3, Mark Millard4, Jacob Turner5, HyeMee Joo1,2, SangKon Oh1,2.   

Abstract

Entities:  

Keywords:  asthma; biomarkers; body mass index; immunoglobulin E; obesity; omalizumab

Year:  2020        PMID： 32585057     DOI： 10.1111/cea.13696

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN： 0954-7894            Impact factor:   5.018


× No keyword cloud information.
  4 in total

Review 1.  Sex, Allergic Diseases and Omalizumab.

Authors:  Maria Maddalena Sirufo; Francesca De Pietro; Lia Ginaldi; Massimo De Martinis
Journal:  Biomedicines       Date:  2022-01-29

2.  Predictors of a Minimal Clinically Important Difference Following Omalizumab Treatment in Adult Patients With Severe Allergic Asthma.

Authors:  Wei-Chang Huang; Pin-Kuei Fu; Ming-Cheng Chan; Chun-Shih Chin; Wen-Nan Huang; Kuo-Lung Lai; Jiun-Long Wang; Wei-Ting Hung; Yi-Da Wu; Chia-Wei Hsieh; Ming-Feng Wu; Yi-Hsing Chen; Jeng-Yuan Hsu
Journal:  Front Med (Lausanne)       Date:  2022-01-03

3.  Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.

Authors:  Misbah Noshela Ghazanfar; Ewa Anna Bartko; Nicolai Skovbjerg Arildsen; Lars K Poulsen; Bettina Margrethe Jensen; Christian Enevold; Jesper Grønlund Holm; Anders Woetmann; Niels Ødum; Simon Francis Thomsen
Journal:  Clin Exp Allergy       Date:  2022-03-22       Impact factor: 5.401

4.  Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy.

Authors:  Laura Bergantini; Miriana d'Alessandro; Paolo Cameli; Tommaso Pianigiani; Matteo Fanetti; Piersante Sestini; Elena Bargagli
Journal:  Mol Diagn Ther       Date:  2021-08-03       Impact factor: 4.074
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.